Navigation Links
Cepheid Reports 2013 First Quarter Results
Date:4/18/2013

7.421.428%Non-Clinical & Other

0.91.5-40%Total International28.322.924%Total Sales$
91.9$
77.319%


  • During the quarter, Cepheid installed a total of 125 GeneXpert systems in its commercial Clinical business.  Additionally, the Company placed a total of 157 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.  Including the HBDC systems, a cumulative total of 4,117 GeneXpert systems have been placed worldwide as of March 31, 2013.
  • GAAP gross margin on sales was 53% and non-GAAP gross margin on sales was 55%, which compares to 54% and 55%, respectively, in the first quarter of 2012. 
  • Cash and cash equivalents were $102.0 million as of March 31, 2013.
  • DSO was 45 days.
  • Business OutlookFor the fiscal year ending December 31, 2013, the Company continues to expect:

  • Total revenue to be in the range of $375 to $385 million;
  • Net income to range from a net loss of $(0.05) to net income of $0.01 per share; 
  • Non-GAAP net income in the range of $0.41 to $0.46 per share. 
  • Expected non-GAAP net income excludes approximately $29 million related to stock compensation expense and approximately $4 million related to the amortization of acquired intangibles.  The fully diluted share count for the year is expected to be approximately 72 million, except in the event of a GAAP loss where the share count would be approximately 67 million shares.

    The following table reconciles net income (loss) per share to the non-GAAP net income per share range:Guidance Range for YearEnding December 31, 2013Low HighNet Income (Loss) Per Share$
    (0.05)$
    .01Stock Compensation Expense0.400.39Amortization of Purchased Intangible Assets0.060.06Non-GAAP Measure of Net Income Per Share$
    .41$
    .46Accessing Cepheid's 2013 First Quarter Results Conference CallThe Company will host a management presentation at 2 p.m. Pacific Time on
    '/>"/>

    SOURCE Cepheid
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
    2. Cepheid Announces Board of Directors Changes
    3. Cepheid Reports 2012 Second Quarter Results
    4. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
    5. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
    6. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
    7. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
    8. Cepheid to Webcast Upcoming Financial Presentations
    9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
    10. Cepheid Welcomes Senior Vice President of Human Resources
    11. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/24/2014)... DUBAI , UAE, November 24, 2014 ... prestigious "Sheikh Hamdan Bin Rashid Al Maktoum Awards for ... in Dubai, United Arab Emirates , ... http://photos.prnewswire.com/prnh/20141124/717861 ) , The Carter Center ... Medical Services is actively involved in numerous programs that ...
    (Date:11/24/2014)... Belgium , Nov. 24, 2014 VolitionRx ... developing diagnostic tests for cancer and other conditions, today announced ... presented at the Science for Business BioWin Day 2014, being ... . The data come from VolitionRx,s lung cancer pilot study, ... of the Centre Hospitalier Universitaire (CHU) de Liege in ...
    (Date:11/24/2014)... FRANCISCO, Calif. , Nov. 24, 2014   Veracyte, ... Bonnie H. Anderson , president and chief executive officer, ... Jaffray 26 th Annual Healthcare Conference on Tuesday, December ... York . The live audio webcast and ... http://investor.veracyte.com . Please connect to the website at least ...
    (Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
    Breaking Biology Technology:Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
    ... 21, 2011 MDOUTLOOK®, the global oncology intelligence initiative ... Annual Quick Poll research launched immediately following this month,s ... (ASCO) in Chicago. These Quick Polls expand on previous ... annual meetings, as well as similar efforts after the ...
    ... 21, 2011 Waife & Associates, Inc. (W&A), change ... is adding the consulting practice of Mark Di Ianni, ... Di Ianni has been a senior executive in the ... and/or managing a series of successful companies. In recent ...
    ... ROCKVILLE, Md., June 21, 2011 For successful ... needs to be aligned from concept through the ... (RAPS)webinar, participants will learn why Regulatory and Marketing ... product claims and promote the product for both ...
    Cached Biology Technology:MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics 2MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics 3Waife & Associates, Inc. Adds Mark Di Ianni as Principal Consultant 2How-To RAPS Webinar June 30: Regulatory and Marketing Symbiosis from Concept to Launch 2
    (Date:11/21/2014)... C-Labs LLC, a leading provider of remote ... today announced the appointment of John Traynor ... strategic advisor to the firm, Mr. Traynor will now ... based out of the C-Labs office in ... Muench , Chief Executive Officer. Photo - ...
    (Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
    (Date:11/7/2014)... Researchers led by Dr. Debra Auguste, associate professor, ... at The City College of New York, have ... treatment for one of the most aggressive forms ... (TNBCs) have a high mortality rate owing to ... effective therapeutic options. However, Professor Auguste,s team, discovered ...
    Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
    ... MADISON, WI, SEPTEMBER 2, 2008 Varying the rate of ... intuitive sense, as farmers have long observed differences in ... The availability of spatial yield information from combines equipped ... improved management. So, optimizing inputs to match ...
    ... biomarkers for the detection of diseases including cancer and ... Cell Research . The findings pave the way ... are a class of naturally occurring small non-coding RNAs ... reporting individual miRNAs as diagnostic biomarkers of specific cancers ...
    ... University nanophotonics pioneer Naomi Halas has won one of ... the University of Pennsylvania,s Nano/Bio Interface Center (NBIC). ... the innovative synthesis of nanostructures. She will accept the ... ceremonies Oct. 29 in Philadelphia. Halas is the ...
    Cached Biology News:A little nitrogen can go a long way 2A little nitrogen can go a long way 3
    UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
    AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
    ...
    ... Fixation Buffer, used in conjunction with ... can be used to fix and ... staining of cytokines and other cytoplasmic ... been specially formulated for reducing non-specific ...
    Biology Products: